iGeneTech Bioscience Co., Ltd.
EN

Solid Tumor Mid Panel

Overview
Performance
Ordering Info
Resources
Articles

Overview

TargetSeq® Solid Tumor Mid Panel covers 122 gene coding regions related to solid tumors, 10 hotspot fusion gene intron regions, 19 classic microsatellite sites, and 219 chemotherapy-related sites.

NCC-Panel

Product Parameter

Panel Number

T1288V1

Technical Platform
TargetSeq® Hybridization Capture Sequencing
Coverage Size

438.3 kb

Reference Database
RefSeq
Reference Genome
GRCh37 (hg19)
Coverage

CDS region of 122 genes, 10 hotspot fusion gene intron regions, 19 MSI and 219 chemotherapy-related sites.

Storage

-20℃±5℃

Sequence Platform
Illumina / MGI
Recommend Sequencing Read Length
PE150
Recommend Sequencing Data Size and Depth

1.5Gb/1,000X


Request a Consultation

Advantages

  • Selected coverage of 122 key pan-cancer genes;

  • Simultaneous detection of various variant types including SNP/Indel, CNV, Fusion, and MSI.

  • Coupled with high-efficiency library preparation and hybrid capture reagents, it accurately targets low-abundance variants.


Request a Consultation

Performance

Performance

Capture Performance Test

image.png

Figure 1. Test of Capture Data Performance of gDNA Reference Standards. gDNA positive reference standards (Shuimu Jiheng, PSC500) were used to construct libraries with an input amount of 100 ng, followed by hybrid capture and sequencing on the Illumina NovaSeq 6000 with PE150.


Mutation Detection

Table 1. Detection results of mutation sites in gDNA positive reference standards

Gene

Variant

Expected Allelic Frequency

Reported Allelic Frequency

EGFR

L858R

1.0%

0.9%

KRAS

A146T

1.0%

1.4%

NRAS

Q61K

1.0%

0.9%

EGFR

T790M

2.0%

1.9%

EGFR

E746_A750del

2.0%

1.5%

FLT3

I836del

2.0%

1.8%

KIT

D816V

2.0%

2.3%

KRAS

G12D

2.0%

1.6%

EGFR

A767_V769dup

3.0%

1.9%

EGFR

G719S

4.0%

4.5%

EML4-ALK

Fusion

5.0%

3.6%

Note: Results of comparative analysis on detection of mutation sites in positive standards. Shuimu Jiheng gDNA and cfDNA positive standards were used for testing, with sequencing performed on the Illumina NovaSeq 6000 platform (PE150). All positive mutation sites were detected, which was consistent with the expected results.


Learn more about TargetSeq® Solid Tumor Mid Panel

Ordering Info

TargetSeq® Solid Tumor Mid Panel
Product NamePanel NumberSetCat. No

TargetSeq® Solid Tumor Mid Panel

T1288V1

16 rxn

PH2002101

96 rxn

PH2002102


Resources

Demo DataSet
  • TargetSeq® Solid Tumor Mid Panel (T1288V1) demo data
    TargetSeq® Solid Tumor Mid Panel (T1288V1) demo data
bed File
  • TargetSeq® Solid Tumor Mid Panel (T1288V1) bed file
    TargetSeq® Solid Tumor Mid Panel (T1288V1) bed file

Articles

Binsheng Gong; Dan Li; Rebecca Kusko; Natalia Novoradovskaya; Yifan Zhang; Shangzi Wang; Carlos Pabón-Peña; Zhihong Zhang; Kevin Lai; Wanshi Cai; Jennifer S. LoCoco; Eric Lader; Todd A. Richmond; Vinay K. Mittal; Liang-Chun Liu; Donald J. Johann; James C. Willey; Pierre R. Bushel; Ying Yu; Chang Xu; Guangchun Chen; Daniel Burgess; Simon Cawley; Kristina Giorda; Nathan Haseley; Fujun Qiu; Katherine Wilkins; Hanane Arib; Claire Attwooll; Kevin Babson; Longlong Bao; Wenjun Bao; Anne Bergstrom Lucas; Hunter Best; Ambica Bhandari; Halil Bisgin; James Blackburn; Thomas M. Blomquist; Lisa Boardman; Blake Burgher; Daniel J. Butler; Chia-Jung Chang; Alka Chaubey; Tao Chen; Marco Chierici; Christopher R. Chin; Devin Close; Jeffrey Conroy; Jessica Cooley Coleman; Daniel J. Craig; Erin Crawford; Angela del Pozo; Ira W. Deveson; Daniel Duncan; Agda Karina Eterovic; Xiaohui Fan; Jonathan Foox; Cesare Furlanello; Abhisek Ghosal; Sean Glenn; Meijian Guan; Christine Haag; Xinyi Hang; Scott Happe; Britt
Genome Biology 2021;22(1):109 DOI:10.1186/s13059-021-02315-0
Binsheng Gong; Rebecca Kusko; Wendell Jones; Weida Tong; Joshua Xu
Scientific Data 2022;9(1):288 DOI:10.1038/s41597-022-01359-6